Positive ER Expression Assessed by 18F-FES PET/CT in the MBC with ER-negative Primary Tumor

Positive Estrogen Receptor (ER) Expression Assessed by 18F-fluoroestradiol Positron Emission Tomography/Computed Tomography (18F-FES PET/CT) in the Metastatic Breast Cancer (MBC) with ER- Negative Primary Tumor

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06344767

Enrollment

Registered

2024-04-03

Start date

2023-09-01

Completion date

2024-05-05

Last updated

2024-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

To investigate the treatment pattern and efficacy of patients with negative primary ER lesion but positive ER expression in MBC using a novel convenient way of 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients diagnosed with breast cancer (according to International Classification of Diseases 10th Revision) with confirmed metastasis, regardless of being de novo diagnosed or progressed from a nonmetastatic stage. * MBC patients who underwent 18F-FES PET/CT at the Fudan University Shanghai Cancer Center between 2012 and 2023 * Patients diagnosed with primary ER-negative tumor and who were yet to receive any systemic therapy during the advanced stage

Exclusion criteria

Patients with incomplete medical records and those diagnosed with secondary primary tumors

Design outcomes

Primary

Measure	Time frame	Description
Progression free survival (PFS)	6 weeks	Progression free survival

Secondary

Measure	Time frame	Description
Adverse events	6 weeks	Number of participants with treatment-related adverse events as assessed by CTCAE v 5.0

Countries

China

Outcome results